Stem cell therapy for pulmonary fibrosis and interstitial lung disease. MSC treatments target the TGF-β1/Smad fibrotic pathway, break down existing lung scarring through MMP activation, and promote alveolar epithelial regeneration. Evidence-based regenerative approach for IPF, NSIP, and post-COVID lung fibrosis.
Stem cell therapy for pulmonary fibrosis at StemCell Longevita in Istanbul targets the fibrotic pathways destroying lung tissue, promoting alveolar repair and improving respiratory function. Our MSC treatments offer hope for patients with idiopathic pulmonary fibrosis (IPF), post-COVID lung fibrosis, and other interstitial lung diseases.
Pulmonary fibrosis involves progressive scarring of lung tissue, driven by overactive fibrotic pathways (TGF-β1/Smad signaling). MSCs inhibit these fibrotic pathways, break down existing scar tissue through MMP (matrix metalloproteinase) activation, regenerate damaged alveolar epithelium, and reduce the chronic inflammation perpetuating fibrosis. This multi-mechanism approach addresses both the cause and consequences of lung scarring.
Patients with IPF, NSIP, connective tissue disease-related ILD, post-COVID pulmonary fibrosis, and other interstitial lung diseases. Most beneficial in mild-to-moderate disease where functional lung tissue remains. Patients experiencing progressive decline despite antifibrotic therapy (pirfenidone, nintedanib) may benefit from MSC co-therapy.
After review of HRCT imaging, pulmonary function tests, and 6-minute walk test results, treatment involves IV MSC infusion. The pulmonary capillary bed captures a significant proportion of IV-infused cells, ensuring targeted delivery to damaged lung tissue.
Stabilized or improved lung function (FVC), improved exercise capacity, reduced oxygen supplementation needs, and enhanced quality of life within 3-6 months. HRCT may show reduced ground glass opacities and honeycomb changes in some patients.
Istanbul's pulmonology centers provide advanced HRCT imaging and pulmonary function testing. Our anti-fibrotic MSC protocols offer an alternative at 60-80% lower cost than Western specialty centers.
Pulmonary fibrosis stem cell therapy from €7,500, including pulmonary assessment, MSC infusion, hotel, transfers, and 12-month respiratory follow-up.
Related treatments: Diabetes Stem Cell Therapy | Hepatitis Stem Cell Therapy | Liver Disease Stem Cell Therapy | COPD Stem Cell Therapy | Kidney Disease Stem Cell Therapy
